Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression
- 1 January 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 123 (1) , 9-14
- https://doi.org/10.1046/j.1365-2249.2001.01435.x
Abstract
MoAbs against tumour-associated antigens (TAA) may be useful for the treatment of colorectal cancer. Since an increased expression of TAA may lead to enhanced antibody-dependent cellular cytotoxicity we examined whether the cytokines IL-2, IL-4, IL-6, IL-10, IL-12, interferon-alpha (IFN-α), IFN-γ, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and tumour necrosis factor-alpha can influence EpCAM and LewisY expression on the surface of the colorectal carcinoma cell lines HT29, LoVo and SW480. We found that only IFN-α increased significantly whereas IL-4 decreased both EpCAM and LewisY expression. IFN-γ significantly increased LewisY expression only. When tumour cells were treated with MoAb, the LewisY-specific MoAb BR55-2 down-regulated LewisY antigen expression, whereas MoAb 17-1A, which binds to EpCAM, up-regulated this TAA after 3 days of culture. The cytokines IFN-α or IFN-γ combined with MoAb 17-1A enhanced further slightly the expression of EpCAM. In additional experiments with chemotherapeutic drugs commonly used for the treatment of colorectal cancer, we found that 5-fluorouracil, mitomycin-C and oxaliplatin up-regulated EpCAM and LewisY antigen expression. Raltitrexed enhanced LewisY and down-regulated EpCAM expression, whereas CPT-11 had no influence at all. The highest expression for EpCAM on HT29 cells was achieved by the combination of IFN-α, 5-fluorouracil and MoAb 17-1A. Our results may be useful for defining combinations of biological and chemotherapeutic drugs for the treatment of colorectal cancer. Further trials should evaluate to what extent these combinations enhance antibody-dependent cellular cytotoxicity.Keywords
This publication has 55 references indexed in Scilit:
- Augmentation of 17–1A–Induced Antibody–Dependent Cellular Cytotoxicity by the Triple Cytokine Combination of Interferon-α, Interleukin-2, and Interleukin-12Journal of Immunotherapy, 2000
- Enhancement of Antibody Dependent Cellular Cytotoxicity (ADCC) by Combination of CytokinesHybridoma, 1999
- Modulation of Tumor-Associated Antigen Expression on Human Pancreatic and Prostate Carcinoma Cells In Vitro by α- and γ-InterferonsJournal of Immunotherapy, 1995
- Interferon ? enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancerCancer Immunology, Immunotherapy, 1995
- Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptorsInternational Journal of Cancer, 1994
- Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2Cancer Immunology, Immunotherapy, 1994
- Human melanoma cells express a functional interleukin‐2 receptorInternational Journal of Cancer, 1993
- In vitro and in vivo regulation of tumor antigen expression by human recombinant interferonsInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
- Expression of transferrin- and interleukin-2- receptors, and HLA-DR in human lung carcinomaExperimental pathology, 1991
- Enhancement of carcinoembryonic antigen expression by interferonInternational Journal of Cancer, 1979